Expanding the adoption of MACI Arthro, an FDA-approved arthroscopic delivery method for knee cartilage repair, by training orthopedic surgeons.

Expected impact: Unlocks growth in minimally invasive procedures, driving higher biopsy and implant volumes as trained surgeons show increased utilization.

Expanding the MACI sales force to increase territory coverage and surgeon penetration.

Expected impact: Supports volume growth and deeper market penetration across under-penetrated orthopedic accounts.

Advancing the clinical development of MACI for a potential ankle cartilage defect indication through the Phase III MASCOT clinical study.

Expected impact: Targets an estimated addressable market opportunity of more than $1 billion for the potential ankle indication.